Suppression of fasting small intestinal motility by exogenous GLP-1 is also evident in healthy humans and those with irritable bowel syndrome, manifested by a reduction in the frequency of MMCs in a dose-dependent manner [76].Indeed, the GLP-1 analogue, ROSE-010, has been reported to be more effective than placebo at relieving abdominutesal pain in irritable bowel syndrome patients [101]. This evidence concerns the gene GLP1R and irritable bowel syndrome.